T(14;16)-positive multiple myeloma shows negativity for CD56 expression and unfavorable outcome even in the era of novel drugs

T. Narita, A. Inagaki, T. Kobayashi, Y. Kuroda, T. Fukushima, M. Nezu, S. Fuchida, H. Sakai, N. Sekiguchi, I. Sugiura, Yoshinobu Maeda, H. Takamatsu, N. Tsukamoto, D. Maruyama, Y. Kubota, M. Kojima, K. Sunami, T. Ono, M. Ri, K. TobinaiS. Iida

Research output: Contribution to journalArticle

15 Citations (Scopus)
Original languageEnglish
Article numbere285
JournalBlood Cancer Journal
Volume5
Issue number2
DOIs
Publication statusPublished - Jan 1 2015

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Narita, T., Inagaki, A., Kobayashi, T., Kuroda, Y., Fukushima, T., Nezu, M., Fuchida, S., Sakai, H., Sekiguchi, N., Sugiura, I., Maeda, Y., Takamatsu, H., Tsukamoto, N., Maruyama, D., Kubota, Y., Kojima, M., Sunami, K., Ono, T., Ri, M., ... Iida, S. (2015). T(14;16)-positive multiple myeloma shows negativity for CD56 expression and unfavorable outcome even in the era of novel drugs. Blood Cancer Journal, 5(2), [e285]. https://doi.org/10.1038/bcj.2015.6